Skip to main content
Fig. 6 | Journal for ImmunoTherapy of Cancer

Fig. 6

From: The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation

Fig. 6

ATOR-1015 depletes Tregs and activates effector T cells in the tumor. Homozygous hOX40tg mice were inoculated with MC38 cells day 0 and treated ip with ATOR-1015, monotargeting anti-CTLA-4 and anti-OX40 antibodies (248 μg for bsAbs or 200 μg for mAbs) or vehicle on days 10, 14 and, 18. Twenty-four hours after the last injection, the tumors and spleens were harvested, and stained for Treg and effector T cell markers. (a-b) CD8+ T cell/Treg ratio in the tumor and spleen. (c) Percentage of Tregs (of CD45+ cells) in tumors. (d) Percentage CD8+ T cells (of CD45+ cells) in tumors. (e-f) Expression of CD107a and Granzyme B on CD8+ T cells in the tumors. All data presented as mean and each dot represents one animal. Statistical differences were analyzed using Mann-Whitney, two-tailed test, (*, p < 0–05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001)

Back to article page